Low utilisation of unactivated protein C in a patient with meningococcal septic shock and disseminated intravascular coagulation

Acta Anaesthesiologica Scandinavica

Volumn 47, Issue 7, 2003, Pages 897-900

  Lignell, A ^a   Siegbahn, A ^a   Stridsberg, M ^a   Pauksen, K ^a   Gedeborg, R ^a   SjöLin, Jan ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Activation; Pharmacokinetics; Protein C; Septic shock

Indexed keywords

AMPICILLIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CEFOTAXIME; CORTICOSTEROID; DOBUTAMINE; DOPAMINE; FIBRINOGEN; HAEMOCOMPLETTAN P; NORADRENALIN; PROTEIN C; PROTHROMPLEX T;

ADULT; ARTICLE; CASE REPORT; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG HALF LIFE; FEMALE; HEMOSTASIS; HUMAN; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTHROMBIN TIME; SEPTIC SHOCK; THROMBOCYTE COUNT;

ADULT; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRIN; HALF-LIFE; HUMANS; MENINGOCOCCAL INFECTIONS; PROTEIN C; SHOCK, SEPTIC;

EID: 0042347994     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-6576.2003.00075.x     Document Type: Article

References (11)

1. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001; 29: 48-52.
2. Fourrier F, Chopin C, Goudemand J et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C and protein S deficiencies. Chest 1992; 101: 816-23.
3. Lorente JA, Garcia-Frade LJ, Landin L et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103: 1536-42.
4. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP. An open-label study of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96: 3719-24.
5. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
6. Boehme MW, Deng Y, Raeth U et al. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology 1996; 87: 134-40.
7. Faust SN, Levin M, Harrison OB et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345: 408-16.
8. Hazelzet JA, de Kleijn ED, de Groot R. Endothelial protein C activation in meningococcal sepsis. N Engl J Med 2001; 345: 1776-7.
9. Auberger K. Evaluation of a new protein-C concentrate and comparison of protein-C assays in a child with congenital protein-C deficiency. Ann Hematol 1992; 64: 146-51.
10. Monagle P, Andrew M, Halton J et al. Homozygous protein C deficiency: Description of a new mutation and successful treatment with low molecular weight heparin. Thromb Haemost 1998; 79: 756-61.
11. Hodgson A, Ryan T, Moriarty J, Mellotte G, Murphy C, Smith OP. Plasma exchange as a source of protein C for acute onset protein C pathway failure. Br J Haematol 2002; 116: 905-8.